10-Q: Arvinas Reports Q1 2026 Results, VEPPANU FDA Approval

Arvinas announces Q1 2026 financial results, highlighting significant revenue decrease offset by progress in clinical pipeline and the landmark FDA approval of VEPPANU.

Summary

• Arvinas reported a substantial decrease in revenue for the first quarter of 2026, totaling $15.6 million compared to $188.8 million in the prior year period, primarily due to changes in revenue recognition for the Vepdegestrant (ARV-471) Collaboration Agreement.
• Research and development expenses decreased to $60.3 million from $90.8 million, driven by lower compensation and external expenses.
• General and administrative expenses also decreased to $19.1 million from $26.6 million, attributed to reduced professional fees and commercial operations costs.
• The company ended the quarter with $614.9 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the second half of 2028.
• A significant development was the FDA approval of VEPPANU (vepdegestrant) for advanced or metastatic breast cancer, marking the first FDA-approved PROTAC protein degrader.
• Arvinas is progressing multiple product candidates, including ARV-102 for neurodegenerative diseases, ARV-806 for KRAS G12D-mutated cancers, ARV-393 for non-Hodgkin lymphoma, and ARV-027 for Spinal-Bulbar Muscular Atrophy.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed sentiment. The FDA approval of VEPPANU is a major positive, but the significant revenue drop and continued net loss present considerable financial challenges.

Positives

• FDA approval of VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, representing a significant therapeutic advancement and the first PROTAC protein degrader approved.
• VEPPANU approval received ahead of the PDUFA date, indicating strong regulatory engagement.
• Positive topline results from the Phase 3 VERITAC-2 clinical trial for VEPPANU, showing a 43% reduction in the risk of disease progression or death compared to fulvestrant.
• VEPPANU added to the NCCN Clinical Practice Guidelines for Breast Cancer as a Category 2A treatment option.
• ARV-102 Phase 1 clinical trial in Parkinson's disease patients demonstrated good tolerability, brain penetration, and dose-dependent LRRK2 degradation.
• ARV-806 Phase 1 clinical trial in solid tumors with KRAS G12D mutations completed dose escalation, with initial clinical data anticipated in 2026.
• ARV-393 Phase 1 clinical trial in relapsed/refractory NHL showed early responses, supporting continued dose escalation and initiation of a combination cohort with glofitamab.
• ARV-027 preclinical data in an SBMA mouse model showed meaningful functional improvements and extended survival.
• ARV-6723 preclinical data supports clinical investigation in solid tumors, demonstrating potent degradation and anti-tumor immune responses.
• Cash runway extended into the second half of 2028 with $614.9 million in cash, cash equivalents, and marketable securities.
• Successful transition of luxdegalutamide (ARV-766) development to Novartis.
• Appointment of Randy Teel as President and CEO, and Briggs Morrison as Chair of the Board.

Negatives

• Significant decrease in revenue to $15.6 million from $188.8 million year-over-year, primarily due to changes in revenue recognition for the Vepdegestrant (ARV-471) Collaboration Agreement.
• Net loss of $57.6 million for the quarter, compared to a net income of $82.9 million in the prior year period.
• The company continues to incur substantial operating losses and expects to do so for the foreseeable future.
• The ARV-102 Phase 1b clinical trial in PSP patients is on clinical hold pending FDA review of toxicology data.
• The company is planning to select a third party for the commercialization and further development of VEPPANU, indicating a reliance on external partners and potential loss of control over commercialization decisions.
• The company has undergone significant workforce reductions (33% in April 2025 and an additional 15% announced in September 2025) to optimize costs.

Risks

• The success of VEPPANU depends on identifying and executing a commercialization arrangement with a third party, with no assurance of finding a suitable partner or favorable terms.
• The company has limited control over the commercialization and development decisions made by a future third-party partner for VEPPANU.
• Continued reliance on external funding is necessary, as the company expects to incur significant operating losses for the foreseeable future.
• Clinical trials may face delays or unexpected outcomes, impacting development timelines and costs.
• Failure to obtain regulatory approval for product candidates will prevent revenue generation and profitability.
• Competition from other biotechnology and pharmaceutical companies developing similar therapies.
• The company's ability to manage its workforce reductions and cost optimization efforts effectively.
• The company's dependence on its collaboration partners, such as Pfizer, for the development and commercialization of its products.
• The potential for intellectual property disputes or challenges.
• The company's ability to secure additional funding on acceptable terms, or at all, could impact its ability to continue operations.

Future Outlook

Arvinas anticipates continued substantial increases in research and development expenses as it advances its clinical pipeline, including ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant. The company expects to incur significant operating losses for the foreseeable future and will require substantial additional financing. The company believes its current cash, cash equivalents, and marketable securities will fund operations into the second half of 2028. Decisions regarding VEPPANU's pricing, access, reimbursement, and ex-U.S. regulatory plans will be determined by a selected third-party commercialization partner.

Management Comments

• "We believe that our targeted protein degradation approach is a novel therapeutic modality that may provide distinct advantages over existing therapies and address a broad range of targets, including historically undruggable proteins, in areas of significant unmet need."
• "In the second quarter of 2026, the U.S. Food and Drug Administration, or FDA, approved VEPPANU (vepdegestrant) for the treatment of adults with estrogen receptor-positive, or ER+,/human epidermal growth factor receptor 2-negative, or HER2-, estrogen receptor 1, or ESR1, -mutated advanced or metastatic breast cancer... VEPPANU is the first and only FDA-approved PROTAC protein degrader, a type of heterobifunctional protein degrader therapy."
• "We believe that our cash, cash equivalents and marketable securities as of March 31, 2026 will enable us to fund our planned operating expenses and capital expenditure requirements into the second half of 2028."
• "We expect that all decisions related to pricing, access, reimbursement, and ex-U.S. regulatory plans for VEPPANU will be determined by the selected partner."

Industry Context

StockSavvy.ai notes that Arvinas's VEPPANU approval marks a significant milestone for the PROTAC technology, positioning it as a viable therapeutic modality against traditional small molecule inhibitors and antibodies. The company's continued investment in its PROTAC platform across various indications, including oncology and neurodegenerative diseases, aligns with the industry's trend towards developing novel mechanisms of action to address unmet medical needs.

Comparison to Industry Standards

• VEPPANU's approval as the first PROTAC protein degrader sets a new standard in targeted protein degradation therapies, differentiating it from traditional small molecule inhibitors and antibodies.
• The Phase 3 VERITAC-2 trial results for VEPPANU, showing a 43% reduction in progression-free survival risk compared to fulvestrant, demonstrate a clinically meaningful improvement, exceeding benchmarks for similar breast cancer treatments.
• ARV-102's ability to degrade LRRK2 in CSF in Parkinson's disease patients is a key differentiator, as traditional inhibitors only block kinase activity, whereas degradation targets the entire protein.
• ARV-806's preclinical potency against KRAS G12D is reported to be more than 25 times greater than clinical-stage inhibitors and more than 40 times greater than a leading clinical-stage degrader, indicating a potentially superior therapeutic profile.

Management Changes

Related Party Transactions

• A consulting agreement was entered into with John Houston, Ph.D. (former CEO, current Board member) on February 12, 2026, for consulting and advisory services until March 1, 2027. The company agreed to pay him $457,000 in March 2026 (equivalent to his 2025 bonus), reimburse up to $27,914 for COBRA coverage, and pay $500 per hour for services exceeding eight hours per month. Expenses related to this agreement totaled $0.5 million in Q1 2026.

Stakeholder Impact

• Shareholders: The significant revenue decrease and net loss may impact stock price and investor confidence, although the VEPPANU approval is a major positive development. Continued need for capital raises could dilute existing shareholders.
• Employees: Workforce reductions of 15% announced in September 2025, expected to be completed by Q2 2026, will impact affected employees.
• Partners (Pfizer, Novartis, Yale): Continued collaboration and milestone payments are central to Arvinas's business model. The selection of a third-party commercialization partner for VEPPANU will impact Pfizer and Arvinas.
• Creditors: The company has minimal long-term debt ($0.3 million), so the impact on creditors is likely low.

Next Steps

• Announce selection of a third party for the commercialization and potential further development of VEPPANU.
• Initiate Phase 1b clinical trial for ARV-102 in patients with PSP in the U.S. in the second half of 2026.
• Initiate a registrational trial in PSP in late 2026.
• Share additional biomarker data from the ARV-102 Phase 1 clinical trial in patients with PD in the second half of 2026.
• Share initial clinical data in patients with solid tumors harboring KRAS G12D mutations for ARV-806 in 2026.
• Share updated clinical data from the ongoing Phase 1 clinical trial of ARV-393 in patients with relapsed/refractory NHL at a medical congress in the second half of 2026.
• Initiate a Phase 1 clinical trial of ARV-6723 in patients with advanced solid tumors in mid-2026.

Key Dates

Recommendation

Arvinas presents a mixed picture. The FDA approval of VEPPANU is a significant de-risking event and a major positive for the company's platform. However, the substantial decline in revenue, ongoing net losses, and reliance on future capital raises and third-party commercialization partners introduce considerable uncertainty. While the pipeline shows promise, the path to profitability remains long and fraught with clinical and commercial risks. Therefore, a 'hold' recommendation is appropriate, pending further clarity on VEPPANU's commercialization strategy and the company's ability to manage its cash burn.

Keywords

Arvinas, 10-Q, VEPPANU, vepdegestrant, PROTAC, breast cancer, FDA approval, clinical trials, oncology, biotechnology, ARV-102, ARV-806, ARV-393, ARV-027, Pfizer, Novartis, drug development, financial results